National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 37717-37718 [E9-18025]
Download as PDF
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 74, No. 144 / Wednesday, July 29, 2009 / Notices
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human drug product DUREZOL
(difluprednate ophthalmic emulsion).
DUREZOL is indicated for the treatment
of inflammation and pain associated
with ocular surgery. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for DUREZOL (U.S. Patent
No. 6,114,319) from Senju
Pharmaceutical Co. Ltd., and the Patent
and Trademark Office requested FDA’s
assistance in determining this patent’s
eligibility for patent term restoration. In
a letter dated February 18, 2009, FDA
advised the Patent and Trademark
Office that this human drug product had
undergone a regulatory review period
and that the approval of DUREZOL
represented the first permitted
commercial marketing or use of the
product. Thereafter, the Patent and
Trademark Office requested that FDA
determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
DUREZOL is 560 days. Of this time, 369
days occurred during the testing phase
of the regulatory review period, while
181 days occurred during the approval
phase. These periods of time were
derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: December 13,
2006. FDA has verified the applicant’s
claim that the investigational new drug
application became effective on
December 13, 2006.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: December 26, 2007.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
DUREZOL (NDA 22–212) was initially
submitted on December 26, 2007.
3. The date the application was
approved: June 23, 2008. FDA has
verified the applicant’s claim that NDA
22–212 was approved on June 23, 2008.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
VerDate Nov<24>2008
18:30 Jul 28, 2009
Jkt 217001
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 369 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by September 28, 2009.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
January 25, 2010. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: June 23, 2009.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E9–18034 Filed 7–28–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, July 27,
2009, 9 a.m. to July 28, 2009, 6 p.m.,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on July 1, 2009, 74 FR 31453–
31454.
The meeting will be held August 3,
2009 to August 4, 2009. The meeting
time and location remain the same. The
meeting is closed to the public.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
37717
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–18023 Filed 7–28–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Go Applications.
Date: August 5, 2009.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call)
Contact Person: Raul A Saavedra, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS, NSC; 6001
Executive Blvd., Ste. 3208, Bethesda, MD
20892–9529, 301–496–9223,
saavedrr@ninds.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Go Applications.
Date: August 6, 2009.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call)
Contact Person: Ernest W Lyons, Ph.D.
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3208, MSC 952, Bethesda, MD 20892–
9529, 301–496–4056, lyonse@ninds.nih.gov.
E:\FR\FM\29JYN1.SGM
29JYN1
37718
Federal Register / Vol. 74, No. 144 / Wednesday, July 29, 2009 / Notices
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences; 93.701, ARRA Related
Biomedical Research and Research Support
Awards., National Institutes of Health, HHS)
Financial Management (RB) to the
Office of Operations (RB); moves the
Office of Management (RAM) under the
Office of Operations (RB) and moves the
Office of Information Technology (RAG)
under the Office of Operations (RB).
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–18025 Filed 7–28–09; 8:45 am]
Delete in its entirety and replace with
the following:
The Office of the Administrator (RA)
is headed by the Administrator, Health
Resources and Services Administration,
who reports directly to the Secretary.
The OA includes the following
components:
(1) Immediate Office of the
Administrator (RA);
(2) Office of Equal Opportunity and
Civil Rights (RA2);
(3) Office of Planning and Evaluation
(RA5);
(4) Office of Communications (RA6);
(5) Office of Minority Health and Health
Disparities (RA9);
(6) Office of Legislation (RAE);
(7) Office of International Health Affairs
(RAH).
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, July 28,
2009, 9 a.m. to July 28, 2009, 8 p.m.,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD, 20892
which was published in the Federal
Register on July 17, 2009, 74 FR 34762–
34764.
The meeting will be held August 3,
2009 to August 4, 2009. The meeting
time and location remain the same. The
meeting is closed to the public.
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–18022 Filed 7–28–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
Statement of Organization, Functions
and Delegations of Authority
This notice amends Part R of the
Statement of Organization, Functions
and Delegations of Authority of the
Department of Health and Human
Services (HHS), Health Resources and
Services Administration (HRSA) (60 FR
56605, as amended November 6, 1995;
as last amended at 73 FR 30406–30408
dated May 27, 2008).
This notice reflects organizational
changes in the Health Resources and
Services Administration. Specifically,
this notice renames the Office of
VerDate Nov<24>2008
18:30 Jul 28, 2009
Jkt 217001
Chapter RA—Office of the
Administrator
Section RA–10, Organization
Chapter RB—Office of Operations
Section RB–10, Organization
Delete in its entirety and replace with
the following:
The Office of Operations (RB) is
headed by the Chief Operating Officer
who reports directly to the
Administrator, Health Resources and
Services Administration. The Office of
Operations includes the following
components:
(1) Office of the Chief Operating Officer
(RB);
(2) Office of Budget (RB1);
(3) Office of Financial Policy and
Controls (RB2);
(4) Office of Acquisitions Management
and Policy (RB3);
(5) Office of Management (RB4); and
(6) Office of Information Technology
(RB5).
Section RB–20, Functions
(1) Rename the Office of Financial
Management (RB) to the Office of
Operations (RB); (2) delete the
functional statement for the Office of
Management (RAM) and transfer the
function to the Office of Operations
(RB); and (3) delete the functional
statement for the Office of Information
Technology (RAG) and transfer the
function to the Office of Operations
(RB).
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Office of the Chief Operating Officer
(RB)
(1) Provides leadership for operational
activities, interaction and execution of
Agency initiatives across the Health
Resources and Services Administration;
(2) plans, organizes and manages annual
and multi-year budgets and resources
and assures that the conduct of Agency
administrative and financial
management activities effectively
support program operations; (3)
provides an array of Agency-wide
services including information
technology, procurement management,
facilities, workforce management, and
budget execution and formulation; (4)
maintains overall responsibility for
policies, procedures, monitoring of
internal controls and systems related to
payment and disbursement activities;
(5) provides management expertise, staff
advice, and support to the
Administrator in program and policy
formulation and execution; (6) provides
leadership in the development, review
and implementation of policies and
procedures to promote improved
information technology management
capabilities and best practices
throughout HRSA; (7) coordinates IT
workforce issues and works closely with
the Department on IT recruitment and
training issues; and (8) administers
functions of the Chief Financial Office.
Office of Budget (RB1)
(1) Reviews funds control measures to
assure that no program, project or
activity of HRSA obligates or disburses
funds in excess of appropriations or
obligates funds in violation of
authorized purposes; (2) provides
advice and assistance to senior HRSA
management to verify the accuracy,
validity, and technical treatment of
budgetary data in forms, schedules, and
reports, or the legality and propriety of
using funds for specific purposes; (3)
maintains primary liaison to expedite
the flow of financial management work
and materials within the Agency and/or
between Agency components and HHS,
Office of Management and Budget
(OMB), and congressional staff; (4)
provides overall financial-based
analyses and fiduciary review for senior
HRSA management in order to assure
appropriate workforce planning, funds
control guidance, and analytical
technical assistance in all phases of the
budgetary process; and (5) develops the
long-range program and financial plan
for the Agency in collaboration with the
Office of Planning and Evaluation, and
other administrative Agency
components.
E:\FR\FM\29JYN1.SGM
29JYN1
Agencies
[Federal Register Volume 74, Number 144 (Wednesday, July 29, 2009)]
[Notices]
[Pages 37717-37718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18025]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Go Applications.
Date: August 5, 2009.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call)
Contact Person: Raul A Saavedra, Ph.D., Scientific Review
Administrator, Scientific Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS, NSC; 6001 Executive Blvd., Ste. 3208,
Bethesda, MD 20892-9529, 301-496-9223, saavedrr@ninds.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Go Applications.
Date: August 6, 2009.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call)
Contact Person: Ernest W Lyons, Ph.D. Scientific Review
Administrator, Scientific Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 952,
Bethesda, MD 20892-9529, 301-496-4056, lyonse@ninds.nih.gov.
[[Page 37718]]
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences; 93.701, ARRA Related
Biomedical Research and Research Support Awards., National
Institutes of Health, HHS)
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-18025 Filed 7-28-09; 8:45 am]
BILLING CODE 4140-01-P